Corebridge Financial Inc. Lowers Holdings in Harrow, Inc. (NASDAQ:HROW)

Corebridge Financial Inc. reduced its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 7.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,186 shares of the company’s stock after selling 1,146 shares during the period. Corebridge Financial Inc.’s holdings in Harrow were worth $509,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank grew its stake in shares of Harrow by 1.0% in the fourth quarter. Swiss National Bank now owns 59,300 shares of the company’s stock worth $1,990,000 after acquiring an additional 600 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock valued at $253,000 after purchasing an additional 727 shares during the period. HighTower Advisors LLC grew its stake in Harrow by 13.8% during the 4th quarter. HighTower Advisors LLC now owns 10,127 shares of the company’s stock worth $340,000 after purchasing an additional 1,227 shares in the last quarter. Avantax Advisory Services Inc. increased its holdings in Harrow by 11.3% during the 4th quarter. Avantax Advisory Services Inc. now owns 12,534 shares of the company’s stock worth $421,000 after purchasing an additional 1,273 shares during the period. Finally, Teacher Retirement System of Texas raised its position in Harrow by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 8,951 shares of the company’s stock valued at $300,000 after purchasing an additional 1,408 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on HROW shares. B. Riley lowered their price objective on Harrow from $69.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Harrow in a research note on Monday, March 31st.

Harrow Stock Down 3.9 %

Harrow stock opened at $22.20 on Wednesday. The stock has a market cap of $791.52 million, a PE ratio of -23.62 and a beta of 0.46. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock’s fifty day moving average is $27.38 and its two-hundred day moving average is $36.87. Harrow, Inc. has a 1-year low of $9.86 and a 1-year high of $59.23.

Harrow (NASDAQ:HROW) last issued its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. The business had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, sell-side analysts expect that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.